Dr Joan Merrill presents a phase 2 trial use of Iberdomide in patients with #SLE -Novel MOA —> blocks TF Ailos and Ikaros Conclusion -Primary end point was met at week 24 -Effects greater in Aiolos high/Type 2 IFN high -Iverdomdie was tolerated well #Lupus #ACR20 #ACRambassador https://t.co/zpQR9ceV7p

When you counsel patients w/RA, do you warn them that during times of dz flare, their ability to drive may be affected? ...maybe you should based on Abstr#0198 #ACR20 @rheumnow

@RheumNow #acr20 abs0690 ph2a trial: potent reduction of sUA w/URAT1 inhibitor AA882. 100% of pts sUA levels < 6 mg/dL &63% pts < 5 mg/dL compared to febuxostat 50% & 13% respectively. Even more remarkable reduction w/ AA882+febuxostat. Mild to moderate SEs. https://t.co/XrDJXEoC1j

I admit I don’t get it. Warfarin has more cartilage loss than DOACs. Is this real or a reflection of diff access to cheap vs expensive meds?Duration response seen. Need RCT or subanalysis of a fib RCTs. #bestinclass great trainee plenary #934 @RheumNow @CRASCRRheum #ACR20 https://t.co/Eg1ymtDdmI

It's only now we have choices to warfarin that we can realise the effect of vit K blockade on OA. Nested case-control (AF pts, UK primary care): warfarin has risk vs DOAC for end-stage OA (via joint replacement) aOR 1.25 esp knee aOR 1.48 @Tuhina_Neogi #ACR20 ABST0934 @RheumNow https://t.co/XVLG8kIL0W

Plenary session: Dr Ballal presents data showing #warfarin use incr. risk of knee/hip replacements, compared to #DOACs - Nest case-control study in UK THIN database - Risk increases w/ duration of use - Indicates need for well-powered RCT of vit K in OA Abs#0934 #ACR20 @RheumNow https://t.co/YyxDjNQEjx

50% use septra/bactrim in SLE if immunesuppressed. I don’t use it unless if frequent serious infections or bad lungs as I am not convinced about the risk of PCP/PJP v risk of septra with adverse rxns in SLE. I await an admin database to give me the data @RheumNow #ACR20 https://t.co/3s2S9fIUVe

ACPA+ RA should likely NOT taper bDMARDs as less Bio survival if ACPA+ &/or monoRx. Should EULAR guidelines be changed? What about retention with JAKis? #ACR20 @RheumNow @CRASCRRheum abstr804 https://t.co/vjzIIgVJ0s

Great talk by @lovetolearn27 Prosthetic joint infection doubles the risk of venous thromboembolism after revision of knee replacement. 15 yr data New York state -25K revisions! @RheumNow #ACR20 ABS#0960 https://t.co/4PHHSEstKs

Dr. Burmester on serendipity in the development of rheumatologic meds. As we study #COVID19, we need to keep our minds open that we don't always find what we want, but we can always learn something to bring us ahead. #ACR20 @Rheumnow. https://t.co/s5WZEjrbnk

Most ignore pharmacists annoying faxes re safety of QT interval with #hydroxycholoroquine likely the right thing to do! @RheumNow #ACR2020 @CRASCRRheum abstr#431. https://t.co/pXBIDOV2MP

Do pts with RA take their meds & can adherence intervention work? Yes & No. Pts starting new bDMARD RCT of electronic monitoring feedback vs usual care, adherence>80%. Neg RCT Maybe chronic users with poor adherence is group to study abstr#0799 #ACR2020 @RheumNow https://t.co/FyWoBjYnvs

Dr Minalyan and colleagues report rates of gout flare following hospital admission of patients prescribed allopurinol. Gout flare 14 times more likely if allopurinol stopped or omitted. @rheumnow #ACR20 Abstr#688 https://t.co/x3eyX1PLFB

Study of 372 new #hydroxychloroquine users suggests risk of #HCQ #retinopathy at 10yrs is lower compared to previous prevalence-based estimates, although dose >5mg/kg may increase this risk. #RheumTwitter Abs#0540 #ACR20 @RheumNow https://t.co/kOSToCljeq

• Risk of Hydroxychloroquine Retinopathy in the Community - ACR Meeting Abstracts